Courier Capital LLC Has $217,000 Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Courier Capital LLC lifted its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 105.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,000 shares of the medical technology company’s stock after purchasing an additional 20,000 shares during the period. Courier Capital LLC’s holdings in Alphatec were worth $217,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Norden Group LLC boosted its stake in shares of Alphatec by 1,012.2% during the 1st quarter. Norden Group LLC now owns 433,764 shares of the medical technology company’s stock worth $5,982,000 after acquiring an additional 394,763 shares in the last quarter. Insight Folios Inc bought a new stake in Alphatec during the first quarter worth approximately $192,000. Principal Financial Group Inc. grew its holdings in Alphatec by 15.7% during the first quarter. Principal Financial Group Inc. now owns 320,530 shares of the medical technology company’s stock valued at $4,420,000 after purchasing an additional 43,530 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Alphatec by 7.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,031 shares of the medical technology company’s stock valued at $662,000 after purchasing an additional 3,363 shares during the period. Finally, Oak Ridge Investments LLC acquired a new stake in shares of Alphatec in the first quarter worth $1,829,000. 66.35% of the stock is currently owned by institutional investors.

Insider Activity at Alphatec

In related news, Director David M. Demski acquired 50,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was purchased at an average cost of $5.67 per share, for a total transaction of $283,500.00. Following the completion of the purchase, the director now directly owns 288,441 shares of the company’s stock, valued at $1,635,460.47. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 22.80% of the stock is owned by insiders.

Alphatec Trading Up 1.9 %

Shares of ATEC stock opened at $5.23 on Friday. The firm has a fifty day moving average of $5.77 and a 200-day moving average of $8.96. The stock has a market cap of $731.59 million, a price-to-earnings ratio of -3.51 and a beta of 1.39. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $17.34. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.21 and a current ratio of 2.22.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.03). The business had revenue of $145.57 million during the quarter, compared to analyst estimates of $144.55 million. Alphatec had a negative return on equity of 816.57% and a negative net margin of 33.48%. The business’s revenue for the quarter was up 24.5% on a year-over-year basis. During the same period last year, the company earned ($0.43) EPS. On average, equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on ATEC shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Thursday, August 1st. Needham & Company LLC cut their price objective on Alphatec from $23.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, August 22nd. Lake Street Capital decreased their target price on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Barclays initiated coverage on Alphatec in a research report on Monday, July 8th. They issued an “overweight” rating and a $19.00 price target on the stock. Finally, Morgan Stanley cut Alphatec from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Alphatec presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.